Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP10 | P09238 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5208964 | 0.98 | GAA (0.47) | GAAMCOLN3RORCHTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL5208960 | 0.96 | GAA (0.46) | GAAMCOLN3RORCHTR2CHTR2A | |
| SCHEMBL5217170 | 0.84 | MMP3 (0.50) | RORCHTR2CHTR2AKCNH2HTR2B | |
| Hydrochloric Acid SCHEMBL5211487 | 0.82 | MMP3 (0.49) | RORCHTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL5208997 | 0.82 | MMP3 (0.40) | RORCHTR2CHTR2AKCNH2MMP3 | |
| Hydrochloric Acid SCHEMBL5210814 | 0.81 | MMP3 (0.39) | HTR2CHTR2AKCNH2MMP3MMP10 | |
| Hydrochloric Acid SCHEMBL5211483 | 0.81 | MMP3 (0.48) | RORCHTR2CHTR2AKCNH2HTR2B | |
| Hydrochloric Acid SCHEMBL5210809 | 0.80 | MMP3 (0.39) | HTR2CHTR2AKCNH2MMP3MMP10 | |
| SCHEMBL5218102 | 0.80 | DRD2 (0.49) | RORCHTR2CHTR2AKCNH2TSHR | |
| SCHEMBL6743054 | 0.79 | MMP13 (0.46) | GAAMCOLN3RORCOPRM1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641756-B1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | MERCK SHARP & DOHME LTD. (GB) | 2006-09-21 | — | — | US | disclosed |
| CN-1787997-A | 4-arylsulphonylpiperidine derivatives for antagonism of the 5-HT2A receptor | MERCK SHARP & DOHME (GB) | 2006-06-14 | — | — | CN | disclosed |
| EP-1641756-A1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME LTD. (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004101518-A1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | HTR2A, HTR2C, HTR5A | GAA 4670/4885MCOLN3 2592/4885RORC 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.